# Author index

*compiled by Carol Smith*


Abbott, Alison, *see* Schofield, Peter R.
Abbott, Alison, *see* Page, Clive
Abbott, Alison, *see* Struyker Boudier, Harry
Aktories, Klaus and Hall, Alan, Botulinum ADP-ribosyltransferase $C_3$, a new tool to study low molecular weight GTP-binding proteins 415
Allaudeen, H. S., *see* Johnston, Margaret I.
Angus, James A., 5-HT receptors in the coronary circulation 89
Anwyl, Roger, Protein kinase C and long-term potentiation in the hippocampus 236
Arahata, Kiichi and Sugita, Hideo, Dystrophin and the membrane hypothesis of muscular dystrophy 437
Ariëns, E. J., Improper use of proper SIGNS (Letter) 394
Ash, Caroline, Point mutations may account for pyrimethamine resistance 303

Bahnson, Robert R., *see* Lazo, John S.
Balcarek, Joanna, *see* Crooke, Stanley T.
Barlow, Richard and Blake, Joanna F., Hill coefficients and the logistic equation 440
Barnes, Peter J. and Ichinose, Masakazu, $H_3$ receptors in airways (Letter) 264
Beguinot, Laura, *see* Pandiella, Atanasio
Bellomo, Giorgio, *see* Orrenius, Sten
Bennett, C. Frank, *see* Crooke, Stanley T.
Bevan, John A. and Shreeve, S. Martin, Will the true receptor affinity please step forward (Letter) 63
Birdsall, Nigel J. M., Receptor structure: the accelerating impact of molecular biology 50
Blake, Joanna F., *see* Barlow, Richard
Blecher, Stan R., Anonymity in refereeing (Letter) 17
Boddeke, Erik, Hugtenburg, Jacqueline, Jap, Walter, Heynis, Jaap and van Zwieten, Pieter, New anti-ischaemic drugs: cytoprotective action with no primary haemodynamic effects 397
Boobis, Alan R., Fawthrop, Duncan J. and Davies, Donald S., Mechanisms of cell death 275
Bose, D., *see* LaBella, F. S.
Bose, Ranjan, *see* Glavin, Gary B.
Bourgain, René, *see* Braquet, Pierre
Bowery, Norman, $GABA_B$ receptors and their significance in mammalian pharmacology 401
Bowery, Norman G., *see* Tortella, Frank C.
Bowman, W. C., Presynaptic nicotinic autoreceptors (Letter) 136
Bowmer, Christopher J. and Yates, Michael S., Therapeutic potential for new selective adenosine receptor ligands and metabolism inhibitors 339
Boyer, José L., Hepler, John R. and Harden, T. Kendall, Hormone and growth factor receptor-mediated regulation of phospholipase C activity 360
Braquet, Pierre, Paubert-Braquet, Monique, Koltai, Matyas, Bourgain, René, Bussolino, Frederico and Hosford, David, Is there a case for PAF antagonists in the treatment of ischemic states? 23
Brodde, Otto-Erich and Michel, Martin C., Disease states can modify both receptor number and signal transduction pathways 383
Brown, Kenneth, Angiotensin receptors are implicated in the mechanism of *mas* action 87
Bungo, Michael W., *see* Lathers, Claire M.
Burgess, Gillian M., *see* Rüegg, Urs T.
Bussolino, Frederico, *see* Braquet, Pierre

Caldwell, John, Reading the SIGNS in drug names (Letter) 394
Cebon, Jonathan, *see* Morstyn, George
Charles, John B., *see* Lathers, Claire M.
Christen, M-O., *see* DeFeudis, F. V.
Ciardelli, Thomas and Smith, Kendall A., Interleukin 2: prototype for a new generation of immunoactive pharmaceuticals 239
Clarke, David E., Craig, Douglas A. and Fozard, John R., The 5-$HT_4$ receptor: naughty, but nice 385
Cohen, Jack S., Designing antisense oligonucleotides as pharmaceutical agents 435
Collier, Joe and Vallance, Patrick, Second messenger role for NO widens to nervous and immune systems 427
Colquhoun, David, Validity of the operational model (Letter) 17
Cook, Nigel S., *see* Quast, Ulrich
Cooper, Steven J., Drugs interacting with 5-HT systems show promise for treatment of eating disorders 56
Craig, Douglas A., *see* Clarke, David E.
Creveling, Cyrus R., *see* Dixon, Walter R.
Crooke, Stanley T., Mattern, Mike, Sarau, Henry M., Winkler, James D., Balcarek, Joanna, Wong, Angela and Bennett, C. Frank, The signal transduction system of the leukotriene $D_4$ receptor 103

Damsma, G., *see* Westerink, B. H. C.
Davies, Donald S., *see* Boobis, Alan R.
DeBlasi, Antonio, O'Reilly, Kevin and Motulsky, Harvey J., Calculating receptor number from binding experiments using same compound as radioligand and competitor 227
Deckert, J. and Gleiter, C. H., Adenosinergic psychopharmaceuticals? (Letter) 99
DeFeudis, F. V. and Christen, M-O., State- and use-dependent $Ca^{2+}$ antagonists offer hope in control of GI disorders 170
DeFeudis, F. V., The $Ca^{2+}$ channel and 5-$HT_2$ receptor antagonist (s)-emopamil in cerebral ischaemia 215
DeFeudis, F. V., Neurotrophic, neurotoxic and mitogenic activities of 'amyloid' proteins 479
Delahunty, Thérèse Mary, *see* Linden, Joel
di Marzo, Vincenzo, Tippins, John R. and Morris, Howard R., Neuropeptides and inflammatory mediators: bidirectional regulatory mechanisms 91
Dickson, Robert B., Growth factors, oncogenes and anti-oncogenes in cancer 125
Dixon, Walter R. and Creveling, Cyrus R., Archives of the Catecholamine Club, twenty years on 100
Dreyfus, Cheryl F., Effects of nerve growth factor on cholinergic brain neurons 145
Dufton, Mark J. and Harvey, Alan L., The long and the short of snake toxins 258

Efthymiopoulos, C., Piemont, E. and Jung, L., MOM: a computer program for the automatic calculation of statistical moments in pharmacokinetic studies 480
Enna, S. J. and Steranka, Larry R., Receptors and the common cold 387

Fawthrop, Duncan J., *see* Boobis, Alan R.
Feller, S. M., Gagelmann, M. and Forssmann, W. G., Urodilatin: a newly described member of the ANP family 93
Ferrari, Michel D., *see* Saxena, Pramod R.
Field, Hugh J. and Goldthorpe, Siân E., Antiviral drug resistance 333
Fisher, Laurel A., Corticotropin-releasing factor: endocrine and autonomic integration of responses to stress 189
Flack, John D. and Swann, Peter, Validity of animal models in endocrine pathology 301
Forman, Stuart A. and Miller, Keith W., Molecular sites of anesthetic action in postsynaptic nicotinic membranes 447
Forssmann, W. G., *see* Feller, S. M.
Fozard, J. R. and Gray, J. A., 5-$HT_{1C}$ receptor activation: a key step in the initiation of migraine? 307
Fozard, John R., *see* Clarke, David E.
Fredholm, B. B., *see* Stone, T. W.

Freidinger, Roger M., Non-peptide ligands for peptide receptors 270
Fujiwara, Motohatsu, Tsukahara, Tetsuya and Taniguchi, Takashi, α-adrenoceptors in human and animal cerebral arteries: alterations after sympathetic denervation and subarachnoid hemorrhage 329

Gagelmann, M., *see* Feller, S. M.
Gal, Joseph, *see* Simonyi, Miklós
García-Sáinz, J. Adolfo, Intercellular communication within the liver has clinical implications 10
Gardner, Jerry D., *see* Jensen, Robert T.
Gehring, Perry J., Welcome to IUTOX 257
George, Frank R. and Goldberg, Steven R., Genetic approaches to the analysis of addiction processes 78
Glavin, Gary B., Pinsky, Carl and Bose, Ranjan, Mussel poisoning and excitatory amino acid receptors (Letter) 15
Gleiter, C. H., *see* Deckert, J.
Glover, Vivette and Sandler, Merton, Can the vascular and neurogenic theories of migraine finally be reconciled? 1
Godfraind, T. and Govoni, S., Increasing complexity revealed in regulation of $Ca^{2+}$ antagonist receptor 297
Goldberg, Steven R., *see* George, Frank R.
Goldthorpe, Siân E., *see* Field, Hugh J.
Govoni, S., *see* Godfraind, T.
Gray, J. A., *see* Fozard, J. R.
Guengerich, F. Peter, Polymorphism of cytochrome P-450 in humans 107
Gustafsson, Jan-Åke, *see* Zaphiropoulos, Peter G.

Hall, Alan, *see* Aktories, Klaus
Hallam, Trevor J. and Rink, Timothy J., Receptor-mediated $Ca^{2+}$ entry: diversity of function and mechanism 8
Harden, Kendall T., *see* Boyer, José L.
Hartig, Paul R., Molecular biology of 5-HT receptors 64
Harvey, Alan L., *see* Dufton, Mark J.
Haynes, Laurie, Regulation of AChE by a dipeptide (Letter) 136
Henis, Yoav I., Lateral mobility measurement of cell surface components: applications for molecular pharmacology 95
Hepler, John R., *see* Boyer, José L.
Heynis, Jaap, *see* Boddeke, Erik
Hickman, John, Unwarranted pessimism in cancer chemotherapy 167
Hiley, C. Robin, Functional studies on endothelin catch up with molecular biology 47
Holt, Dennis A., *see* Metcalf, Brian W.
Hosford, David, *see* Braquet, Pierre
Hoyer, Daniel and Middlemiss, Derek N., Species differences in the pharmacology of terminal 5-HT autoreceptors in mammalian brain 130
Hugtenburg, Jacqueline, *see* Boddeke, Erik
Ichinose, Masakazu, *see* Barnes, Peter J.

IJzerman, Ad P. and Soudijn, Willem, The antiarrhythmic properties of β-adrenoceptor antagonists 31
Inestrosa, Nibaldo C. and Perelman, Alejandra, Distribution and anchoring of molecular forms of acetylcholinesterase 325
Insel, Paul A., *see* Michel, Martin C.
Izquierdo, Ivan, Mechanism of action of scopolamine as an amnestic 175
Izquierdo, Ivan, Not just a matter of taste 129
Izquierdo, Ivan, Behavioral drug actions and brain lateralization 344
Izquierdo, Ivan, A game with shifting mirrors 473

James, William, *see* Watson, Steve P.
Jap, Walter, *see* Boddeke, Erik
Jenkinson, D. H., Finding affinity constants for agonists by the irreversible antagonist method (Letter) 16
Jensen, Robert T., Wank, Stephen A., Rowley, Wesley H., Sato, Shunsuke and Gardner, Jerry D., Interaction of CCK with pancreatic acinar cells 418
Johnston, Margaret I., Allaudeen, H. S. and Sarver, Nava, HIV proteinase as a target for drug action 305
Joseph, Sunil and Krishnamurthi, Sushila, Pharmacological manipulation of diacylglycerol-dependent protein kinase C (Letter) 396
Jung, L., *see* Efthymiopoulos, C.

Kaakkola, S., *see* Männistö, P. T.
Karaki, Hideaki, $Ca^{2+}$ localization and sensitivity in vascular smooth muscle 320
Kaumann, Alberto J., Is there a third heart β-adrenoceptor? 316
Kenakin, Terry P., Challenges for receptor theory as a tool for drug and drug receptor classification 18
Kirkness, Ewen F., Steroid modulation reveals further complexity of $GABA_A$ receptors 6
Kloog, Yoel and Sokolovsky, Mordechai, Similarities in mode and sites of action of sarafotoxins and endothelins 212
Koltai, Matyas, *see* Braquet, Pierre
Krishnamurthi, Sushila, *see* Joseph, Sunil

La Du, Bert N., Identification of human serum cholinesterase variants using the polymerase chain reaction amplification technique 309
LaBella, F. S., Templeton, J. F., Sashi Kumar, V. P. and Bose, D., Progesterone derivatives that bind to the digitalis receptor 11
Lambert, Jeremy J., *see* Peters, John A.
Lathers, Claire M., Charles, John B. and Bungo, Michael W., Pharmacology in space: PART 1 Influence of adaptive changes on pharmacokinetics 193
Lathers, Claire M., Charles, John B. and Bungo, Michael W., Pharmacology in space: PART 2 Controlling motion sickness 243
Laurenza, Antonio, McHugh Sutkowski, Elizabeth and Seamon, Kenneth B., Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? 442
Layton, Judith, *see* Morstyn, George
Lazo, John S. and Bahnson, Robert R., Pharmacological modulators of DNA-interactive antitumor drugs 369
Levy, Mark A., *see* Metcalf, Brian W.
Lieschke, Graham J., *see* Morstyn, George
Linden, Joel and Delahunty, Thérèse Mary, Receptors that inhibit phosphoinositide breakdown 114
Linden, Joel, Adenosine deaminase for removing adenosine: how much is enough? 260
Lipnick, Robert L., Hans Horst Meyer and the lipoid theory of narcosis 265

Mackay, Dennis, Null method or operational model? (Letter) 16
Majewski, H. and Musgrave, I. F., G proteins and α-adrenoceptor classification (Letter) 14
Männistö, P. T. and Kaakkola, S., New selective COMT inhibitors: useful adjuncts for Parkinson's disease? 54
Masaki, Tomoh, *see* Yanagisawa, Masashi
Mattern, Mike, *see* Crooke, Stanley T.
Max, B., This and That: on color and catecholamines 60
Max, B., This and That: the ethics of experimentation and the legitimate fear of flying 133
Max, B., This and That: sound and silence 220
Max, B., This and That: exotic foods – prophylaxis and peril 313
Max, B., This and That: chocolate addiction, the dual pharmacogenetics of asparagus eaters, and the arithmetic of freedom 390
Max, B., This and That: the war on drugs and the evolution of sulfur 483
McConkey, David, *see* Orrenius, Sten
McHugh Sutkowski, Elizabeth, *see* Laurenza, Antonio
Meldolesi, Jacopo, *see* Vallar, Lucia
Meldolesi, Jacopo, *see* Pandiella, Atanasio
Metcalf, Brian W., Levy, Mark A. and Holt, Dennis A., Inhibitors of steroid 5α-reductase in benign prostatic hyperplasia, male pattern baldness and acne 491
Michel, Martin C. and Insel, Paul A., Are there multiple imidazoline binding sites? 342
Michel, Martin C., *see* Brodde, Otto-Erich
Middlemiss, Derek N., *see* Hoyer, Daniel
Miller, Keith W., *see* Forman, Stuart A.
Milner-White, E. James, Predicting the biologically active conformations of short polypeptides 70
Mitchell, Howard W. and Sparrow, Malcolm, The relevance of pharmacological dose–response curves to airway narrowing 488
Mode, Agneta, *see* Zaphiropoulos, Peter G.
Morris, Howard R., *see* di Marzo, Vincenzo
Morstyn, George, Lieschke, Graham J., Sheridan, William, Layton, Judith and Cebon, Jonathan, Pharmacology of the colony-stimulating factors 154
Motulsky, Harvey J., *see* DeBlasi, Antonio
Musgrave, I. F., *see* Majewski, H.

Nahorski, Stefan R. and Potter, Barry V. L., Molecular recognition of inositol polyphosphates by intracellular receptors and metabolic enzymes 139
Nakatsu, Kanji and Owen, James A., Spreadsheets, data handling and statistics 57
Neumeyer, John L., More education better than new prefixes (Letter) 487
Nicotera, Pierluigi, *see* Orrenius, Sten
Norstedt, Gunnar, *see* Zaphiropoulos, Peter G.

O'Reilly, Kevin, *see* DeBlasi, Antonio
Ormand, J. E., *see* Talley, N. J.
Orme, Michael and Reidenberg, Marcus M., The teaching of clinical pharmacology in Europe and North America 224
Orrenius, Sten, McConkey, David J., Bellomo, Giorgio and Nicotera, Pierluigi, Role of $Ca^{2+}$ in toxic cell killing 281
Ortiz de Montellano, Paul R., Cytochrome P-450 catalysis: radical intermediates and dehydrogenation reactions 354
Owen, James A., *see* Nakatsu, Kanji

Page, Clive and Abbott, Alison, PAF: new antagonists, new roles in disease and a major role in reproductive biology 255
Pandiella, Atanasio, Beguinot, Laura, Vicentini, Lucia M. and Meldolesi, Jacopo, Transmembrane signalling at the

epidermal growth factor receptor 411
Patrono, Carlo, Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back 453
Paubert-Braquet, Monique, *see* Braquet, Pierre
Pellicano, Mario, *see* Tortella, Frank C.
Perelman, Alejandra, *see* Inestrosa, Nibaldo C.
Peters, John A. and Lambert, Jeremy J., Electrophysiology of 5-$HT_3$ receptors in neuronal cell lines 172
Phillis, J. W., *see* Stone, T. W.
Piemont, E., *see* Efthymiopoulos, C.
Pinsky, Carl, *see* Glavin, Gary B.
Plevin, Robin, Robin Plevin replies (Letter) 138
Porreca, Frank, *see* Raffa, Robert B.
Porsolt, R. D., The silent epidemic: the search for treatment of age-related memory impairment 3
Portoghese, Philip S., Bivalent ligands and the message–address concept in the design of selective opioid receptor antagonists 230
Potter, Barry V. L., *see* Nahorski, Stefan R.

**Q**uast, Ulrich and Cook, Nigel S., Moving together: $K^+$ channel openers and ATP-sensitive $K^+$ channels 431

**R**affa, Robert B., Vaught, Jeffry L. and Porreca, Frank, Can equal $pA_2$ values be compatible with receptor differences? 183
Rampe, David and Triggle, David J., New advances in molecular pharmacology of $Ca^{2+}$ channels 388
Rampe, David, *see* Triggle, David J.
Regoli, D., Multiple bradykinin $B_2$ receptors (Letter) 138
Reidenberg, Marcus M., *see* Orme, Michael
Rink, Timothy J., *see* Hallam, Trevor J.
Rowley, Wesley H., *see* Jensen, Robert T.
Rüegg, Urs T. and Burgess, Gillian M., Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kinases 218
Russell, Diane Haddock, New aspects of prolactin and immunity: a lymphocyte-derived prolactin-like product and nuclear protein kinase C activation 40

**S**andler, Merton, *see* Glover, Vivette
Sarau, Henry M., *see* Crooke, Stanley T.
Sarver, Nava, *see* Johnston, Margaret I.
Sashi Kumar, V. P., *see* LaBella, F. S.
Sato, Shunsuke, *see* Jensen, Robert T.
Sawynok, Jana, Sweeney, Marva I. and White, Thomas D., Adenosine release may mediate spinal analgesia by morphine 186
Saxena, Pramod R. and Ferrari, Michel D., 5-$HT_1$-like receptor agonists and the pathophysiology of migraine 200
Schofield, Peter R. and Abbott, Alison, Molecular pharmacology and drug action: structural information casts light on ligand binding 207
Schofield, Peter R., $GABA_A$ receptor: molecular biology reveals a complex picture 476
Schultz, Günter, *see* Seifert, Roland
Scott, J. E., Dopaminergic drug–receptor interactions (Letter) 14
Seamon, Kenneth B., *see* Laurenza, Antonio
Seifert, Roland and Schultz, Günter, Involvement of pyrimidinoceptors in the regulation of cell functions by uridine and by uracil nucleotides 365
Selby, Peter L. and Sherratt, H. Stanley A., Substituted 2-oxiranecarboxylic acids: a new group of candidate hypoglycaemic drugs 495
Shepherd, Virginia L., Intracellular pathways and mechanisms of sorting in receptor-mediated endocytosis 458
Sheridan, William, *see* Morstyn, George
Sherratt, H. Stanley A., *see* Selby, Peter L.
Shreeve, S. Martin, *see* Bevan, John A.
Sieghart, Werner, Multiplicity of $GABA_A$-benzodiazepine receptors 407
Simonyi, Miklòs, Gal, Joseph and Testa, Bernard, Signs of the times: the need for a stereochemically informative generic name system 349
Smith, Kendall A., *see* Ciardelli, Thomas
Sokolovsky, Mordechai, *see* Kloog, Yoel
Soudijn, Willem, *see* IJzerman, Ad P.
Sparrow, Malcolm, *see* Mitchell, Howard W.
Starke, Klaus, The beginnings of hirudin (Letter) 99
Steranka, Larry R., *see* Enna, S. J.
Stone, T. W., Fredholme, B. B. and Phillis, J. W., Adenosine and morphine (Letter) 316
Struyker Boudier, Harry and Abbott, Alison, Novel hypertensive drug reveals unexpected complexities in β-adrenoceptor pharmacology 469
Sugita, Hideo, *see* Arahata, Kiichi
Swann, Peter, *see* Flack, John D.
Sweeney, Marva I., *see* Sawynok, Jana

**T**alley, N. J. and Ormand, J. E., Is antibacterial therapy against *Campylobacter pylori* useful in the treatment of indigestion and chronic peptic ulceration? 36
Taniguchi, Takashi, *see* Fujiwara, Motohatsu
Templeton, J. F., *see* LaBella, F. S.
Testa, Bernard, *see* Simonyi, Miklòs
Timmerman, Hendrick, *see* van der Werf, Jan F.
Timmerman, H., *see* van der Goot, H.
Tippins, John R., *see* di Marzo, Vincenzo
Tortella, Frank C., Pellicano, Mario and Bowery, Norman G., Dextromethorphan and neuromodulation: old drug coughs up new activities 501
Traynor, John, Subtypes of the κ-opioid receptor – fact or fiction? 52
Tricklebank, Mark D., Interactions between dopamine and 5-$HT_3$ receptors suggest new treatments for psychosis and drug addiction 127
Triggle, David J. and Rampe, David, 1,4-Dihydropyridine activators and antagonists: structural and functional distinctions 507
Triggle, David J., *see* Rampe, David
Tsukahara, Tetsuya, *see* Fujiwara, Motohatsu

**U**etrecht, Jack, Mechanism of hypersensitivity reactions: proposed involvement of reactive metabolites generated by activated leukocytes 463

**V**allance, Patrick, *see* Collier, Joe
Vallar, Lucia and Meldolesi, Jacopo, Mechanisms of signal transduction at the dopamine $D_2$ receptor 74
van der Goot, H. and Timmerman, H., Identification system of stereoisomeric drugs (Letter) 486
van der Werf, Jan F. and Timmerman, Hendrick, The histamine $H_3$ receptor: a general presynaptic histaminergic regulatory system? 159
van Loveren, Henk, *see* Vos, Jef
van Zwieten, Pieter, *see* Boddeke, Erik
Vaught, Jeffry L., *see* Raffa, Robert B.
Vermeulen, N. P. E., Analysis of mercapturic acids as a tool in biotransformation, biomonitoring and toxicological studies 177
Vethaak, Dick, *see* Vos, Jef
Vicentini, Lucia M., *see* Pandiella, Atanasio
Vos, Jef, van Loveren, Henk, Wester, Piet and Vethaak, Dick, Toxic effects of environmental chemicals on the immune system 289

**W**ank, Stephen A., *see* Jensen, Robert T.
Watson, Steve P. and James, William, PCR and the cloning of receptor subtype genes 346
Webster, R. A., Tools are inadequate to investigate ACh–DA controversy (Letter) 395
Wessler, Ignaz, Control of transmitter release from the motor nerve by presynatic nicotinic and muscarinic autoreceptors 110
Wester, Piet, *see* Vos, Jef
Westerink, B. H. C. and Damsma, G., Brain microdialysis fails to detect a dopamine–acetylcholine interaction in the basal ganglia 262
Westerink, B. H. C. and Damsma, G., Westerink and Damsma reply (Letter) 396
Whelpton, Robin, Iterative least squares fitting of pH-partition data 182
White, Thomas D., *see* Sawynok, Jana
Whitlock, James P., Jr, The control of cytochrome P-450 gene expression by dioxin 285
Winkler, James D., *see* Crooke, Stanley T.
Wong, Angela, *see* Crooke, Stanley T.
Wonnacott, S., Nicotinic involvement in ACh–DA interaction? (Letter) 395

**Y**anagisawa, Masashi and Masaki, Tomoh, Molecular biology and biochemistry of the endothelins 374
Yates, Michael S., *see* Bowmer, Christopher J.

**Z**aphiropoulos, Peter G., Mode, Agneta, Norstedt, Gunnar and Gustafsson, Jan-Åke, Regulation of sexual differentiation in drug and steroid metabolism 149
Zeelen, F. J., Molecular biological techniques make an impact on medicinal chemistry 472

# Subject index

*compiled by Ann Horrell*

Alphabetic order is word by word, ignoring Greek letters and chemical prefixes. In addition to main subjects of articles, passing mentions of particular and current interest are indexed. Page numbers refer to the page of an article where the subject is first mentioned. American spelling has been adopted in the index, although British spelling will be found in articles by British authors.


ACE (angiotensin-converting enzyme)
  inhibitors: design 270
acebutolol: hypersensitivity 466
acetaminophen *see* paracetamol
acetylcholine
  and Alzheimer's disease 3
  and dopamine system 262 and 395 (Letters)
acetylcholinesterase
  molecular forms 325
  regulation by Gly-Gln 136 (Letter)
acne: and steroid 5α-reductase inhibitors 491
acridines 370
ACTH (adrenocorticotropic hormone): and CRF 189
actinomycin D 370
acyclovir 306
  resistance 335
addiction
  to cocaine 483
  and genetics 78
  and 5-$HT_3$ receptor–dopamine interaction 127
adenosine
  and disease 340
  metabolism 339
  and psychiatric diseases 99 (Letter)
  and spinal analgesia 186 and 316 (Letter)
adenosine deaminase: for removing adenosine 260
adenosine receptors 365
  and phosphoinositide metabolism ($A_1$) 116
  selective ligands 339
adenylyl cyclase (adenylate cyclase)
  and $D_2$ receptor activation 74
  structure 207
ADP-ribosylation: by botulinum toxin 415
adrenaline *see* epinephrine
α-adrenoceptor agonists: and the common cold 387
β-adrenoceptor antagonists
  as antiarrhythmic drugs 31
  in myocardial ischemia 397
  *see also named entries*
β-adrenoceptor downregulation: and tertatolol 470
α-adrenoceptors
  and $Ca^{2+}$ in smooth muscle 320
  in cerebral arteries 329
  and G protein-coupled receptor superfamily ($\alpha_2$) 69
  and $G_i$ ($\alpha_2$) 14 (Letter)
  and imidazolines ($\alpha_2$) 342 and 467 (Errata)
  subtypes ($\alpha_2$) 208
β-adrenoceptors
  and $Ca^{2+}$ in smooth muscle 320
  in heart ($\beta_1$, $\beta_2$, '$\beta_3$') 316
  and immune system 384
  and ischemia 383
  molecular biology/structure ($\beta_1$, $\beta_2$) 52, 64
  and tertatolol 470
aequorin 320
affinity: and competitive binding data 227
agonism: and receptor theory 18
agranulocytosis: and adverse drug reactions 463
AH-25086: and migraine 200
Ah (aromatic hydrocarbon) receptor: and cytochrome P-450 genes 285
AIDS (acquired immune deficiency syndrome)
  and antiviral drug resistance 333
  and GM-CSF 158
  targets for drug action 305
airway narrowing: dose–response curves 488
alcohols: as general anesthetics 450
4-alkyl-1,4-dihydropyridines: and cytochrome P-450 356
allergic disease: and PAF 256
alprenolol 33, 319
Alzheimer's disease 3
  and amyloid proteins 479
  and NGF 145
  and scopolamine amnesia 175
amantadine resistance: in influenza A 333
amifostine 370
aminoglutethimide: hypersensitivity 466
3-aminopropylphosphonic acid 403
aminosalicylic acid: hypersensitivity 466
amiodarone 370
amitriptyline 247
amlodipine 508
amphetamine 244
amsacrine 372
amyloid β-protein: and Alzheimer's disease 479
analgesia, spinal: and morphine 186
anesthetic action
  lipoid theory 265
  molecular basis 447
angina 397
  and $K^+$ channel openers 431
angiotensins (II and III): as mitogens 88
angiotensin receptors
  and *mas* oncogene 87
  and non-peptide ligands (angiotensin II) 270
angiogenesis: and metastasis 127
animal models
  of drug self-administration 80
  of endocrine pathology 301
  of memory 4
anisakiasis: and raw fish 313
anorexia: and 5-HT 56
ANP (atrial natriuretic peptide) family: and urodilatin 93
antiarrhythmic drugs 31
antibacterial therapy: and gastrointestinal disease 36
antibiotics: and *Campylobacter pylori* 39
anticancer drugs
  design 167
  modulation 369
anticancer therapy: and colony-stimulating factors 154
anticholinergics: and the common cold 387
anti-DNA antibodies 464
antihistamines: and the common cold 387
anti-ischemic drugs 397
  *see also* ischemia
antinociception
  and adenosine 186
  and supraspinal δ-opioid receptors 183
antioncogenes 126
antisense oligonucleotides 435
antiviral drug resistance 333
anxiety: and learning 475
AP5 (2-amino-5-phosphonopentanoate): and long-term potentiation 236
3-APA (3-aminopropyl phosphinic acid) 402
apoptosis 279
  and endonuclease activation 283
L-arginine: and synthesis of NO 427
arginine vasopressin: structure 72
aryl hydrocarbon hydroxylase 109
asbestos: and the immune system 291
asparagus 391
asperlicin 272, 421
aspirin: and thrombosis 453
astemizole 246
asthma: and airway smooth muscle 488
atenolol 349
atherosclerosis: and $Ca^{2+}$ antagonists 300
ATP: regulation of cell function 365
autoreceptors
  5-$HT_1$-like 130
  nicotinic and muscarinic 110 and 136 (Letter)
AX-DF 265 432
Axelrod, Julius: and the Catecholamine Club 100

AZT (zidovudine) 306, 333

**B**aclofen 401
barbiturates
  and cytochrome P-450 108
  and $GABA_A$ receptors 6
  as general anesthetics 449
Bay K-8644 509
behavior: animal models 4
behavioral drugs: and brain lateralization 344
behavioral genetics: of addiction 78
benzatropine 247
benzodiazepine receptor ligands: endogenous 473
benzodiazepine receptors 407, 476
  and β-carbolines 473
  types I and II 478
benzodiazepines
  and $GABA_A$ receptors 6, 407
  self-administration by animals 80
β-benzo[*b*]furan-2-yl-GABA 403
benzomorphans 501
benzo[*a*]pyrene
  and cytochrome P-450 109
  and the immune system 291
benzoquinones: and cell death 279
benzotript 421
bicuculline 407
biguanides: and diabetes 495
binding data, competitive: and receptor number and affinity 227
biotransformation: and mercapturic acids 177
bismuth
  as chemoprotector 370
  in non-ulcer dyspepsia 38
bivalent ligands: and drug design 230
bleomycin 372
β-blockers *see* β-adrenoceptor antagonists
Bloom, Floyd: and the Catecholamine Club 100
bombesin: as mitogen 88
BN-52021 23
bopindolol 470
botulinum ADP-ribosyltransferase $C_3$ 415
bradykinin
  as mitogen 88
  and $PIP_2$ hydrolysis 75
  and protein kinase C 219
  and rhinitis 387
  structure 72
bradykinin $B_2$ receptors 138 (Letter)
bradykinin receptor antagonists: and the common cold 387
brain lateralization: and behavioral drugs 344
brain microdialysis: and acetylcholine–dopamine interaction 262 and 395 (Letters)
BRL-24924 (renzapride) 385
BRL-34915 (cromakalim) 35, 431
BRL-43694 (granisetron) 127
$Bt_2cGMP$ 421
Bucholz, Friedrich Adolph: and theory of narcosis 265
bulimia: and 5-HT 56
bungarotoxins (α and κ) 258
bupranolol 318
buspirone 246
buthionine sulfoximine (BSO) 370
*t*-butylbicyclophosphorothionate 6
*t*-butyl hydroperoxide 279
*tert*-butylpindolol 319

**$Ca^{2+}$**
  cytosolic oscillations 9
  receptor-mediated entry 8
$Ca^{2+}$–calmodulin–myosin light chain kinase complex 323
$Ca^{2+}$ channel activators 507
$Ca^{2+}$ channel antagonists 297, 507
  as chemoenhancers 370
  and GI motility disorders 170
  and myocardial ischemia 397
  tissue selectivity 171
  *see also named entries*; 1,4-dihydropyridines; phenylalkylamines
$Ca^{2+}$ channels
  and endothelin 48
  structure 388
  types 297
$Ca^{2+}$ channels, L-type (DHP-sensitive): structure 208, 297, 388
$Ca^{2+}$ channels, receptor-operated: and protein kinase C 219
$Ca^{2+}$ homeostasis
  cell biology 300
  and cell death 275, 281
  and dopamine $D_2$ receptors 74
$Ca^{2+}$ indicators 8, 320
$Ca^{2+}$ localization: in vascular smooth muscle 320
$Ca^{2+}$-mobilizing receptors: and phosphoinositide breakdown 114
$Ca^{2+}$ sensitivity: in vascular smooth muscle 320
cadmium: and the immune system 291
caffeine 390
calcitonin(1–7): structure 72
calpactin 413
*Campylobacter pylori*: and gastrointestinal disease 36
captopril
  enzyme target 306
  hypersensitivity 466
caramiphen 501
carazolol 319
carbachol 75, 489
carbamazepine: hypersensitivity 466
carbetapentane 501
carbobenzoxy-$CCK_{27-32}$-$NH_2$ 421
carbobenzoxy-cystine 421
β-carbolines 407, 473
carbon tetrachloride: and cell death 279
5-carboxamidotryptamine (5-CT) 201, 385
*S*-carboxymethyl cysteine 392
cardiac glycoside recognition site 11
cardiovascular system: and space flight 194
catastrophe theory: and PAF–cytokine networks 26
Catecholamine Club 100
CC-1065: and cancer 168
β-CCB (β-carboline) 473
CCK (cholecystokinin) 418
CCK analogs 421
CCK receptor antagonists 421
CCK receptors
  non-peptide ligands 270
  in pancreas 418
β-CCM (β-carboline) 473
β-CCP (β-carboline) 408
cell–cell fusion: and mobility of glycoproteins 97
cell cycle: and polyamines 42
cell death 275
  role of $Ca^{2+}$ 281
cell proliferation: and the EGF receptor 414
CERM-11956 399
CGP-12177 319
CGRP (calcitonin gene-related peptide): and inflammatory mediators 91
chemoenhancers: in cancer chemotherapy 369
chemoprotectors: in cancer chemotherapy 369
Cheymol, Jean: Obituary 169
chimeric receptors
  EGF receptor–*erb*$B_2$ 126
  EGF–insulin receptor 211
chloramphenicol: stereochemistry 351
4′-chlorodiazepam 477
*p*-chloroisoprenaline 317
chlorpromazine 504
chocolate 390
choline acetyltransferase: and NGF 146
cholinergic neurons 145
ciclosporin 41, 71, 270, 370
ciprofloxacin: enzyme target 306
cisapride 385
cisplatin 372
Cl-218872 408
clinical pharmacology: teaching 224
clinical trials: of cognition-enhancing drugs 5
clomoxir (POCA): and diabetes 497
clonidine 342 and 467 (Errata)
cocaine addiction 483
  and genetics 81
codeine 247, 501
co-dergocrine 247
codergocrine mesylate: and Alheimer's disease 4
colony-stimulating factors
  and receptor-mediated endocytosis 459
  *see also* G-CSF; GM-CSF
common cold 387
COMT (catechol *O*-methyltransferase) inhibitors: and Parkinson's disease 54
coronary circulation: and 5-HT receptors 89
Costa, Erminio: and the Catecholamine Club 100
cough suppressants: and neuromodulation 501
*m*-CPP (*m*-chlorophenylpiperazine): and migraine 2, 307
CPX (8-cyclopentyl 1,3-dipropylxanthine) 340
CR 1409 421
CR 1505 421
Creveling, Cyrus: and the Catecholamine Club 101
CRF (corticotropin-releasing factor): and stress 189
cromakalim (BRL-34915) 35, 431
Crout, Richard: and the Catecholamine Club 100
Cuatrecasas, Pedro: and the Catecholamine Club 100
CV-6209 24
cyclazocine 501
$N^{\alpha}$-(4-cyclohexylbutanoyl)histamine 160
cyclooxygenase
  and aspirin 453
  and PAF 10
cyproheptadine: and migraine 308
cytochalasins: and cell death 281
cytochrome P-450
  gene expression 285
  nomenclature 285
  polymorphisms 107
  reaction mechanisms 354
  sex differences 149
cytokines *see named entries*
cytomegalovirus: drug therapy 336
cytoskeletal organization: and cell death 281

**D**apsone: hypersensitivity 465
data handling: and spreadsheets 57
daunorubicin: resistance 370
deafness 221
debrisoquine: and cytochrome P-450 107
deoxycorticosterone 6
depression: and $GABA_B$ receptors 406
desmethyldiazepam 474
dexamethasone: and cytochrome P-450 288
dexamphetamine 243
dextromethorphan: and neuromodulation 501
dextrorphan 503
diabetes
  induced by streptozocin 302
  new drugs 495
diacylglycerol kinase: inhibitors 396 (Letter)

diazepam: in the brain 473
diazoxide 431
6,6′-dibromoindigotin (Tyrian purple) 61
dichloroisoprenaline 317
1,9-dideoxyforskolin 442
Diehl, Daniel: and theory of narcosis 265
diethyldithiocarbamate 370
digitalis receptor 11
digoxin 13
dihydrofolate reductase
and pyrimethamine resistance 303
3-D structure 472
dihydromuscimol 404
1,4-dihydropyridines (1,4-DHPs)
$Ca^{2+}$ channel activators and antagonists 507
receptor 298
*see also* $Ca^{2+}$ antagonists; *named entries*
dihydrotestosterone 491
dilevalol: stereochemistry 351
diltiazem 215, 371, 507
stereochemistry 350
7,12-dimethylbenzanthracene 291
dimethylformamide 168
dioctanoylethylene glycol 396 (Letter)
dioxin *see* TCDD
diphenhydramine 247
diphenoxylate 247
diphenylhydantoin 501
dipyridamole 341
dissociative anesthetics: self-administration by animals 80
ditolylguanidine 501
diuretics: as chemoenhancers 370
DMCM (β-carboline) 473, 477
domoic acid: and mussel poisoning 15 (Letter)
domperidone 247
dopamine
and acetylcholine 262 and 395 (Letters)
and $5\text{-HT}_3$ receptors 127
dopamine $D_2$ receptor
signal transduction 74, 116
structure 51
dopaminergic drugs: and receptors 14 (Letter)
dose–response curves: and airway narrowing 488
doxepin 247
doxorubicin: resistance 370
DPI 201-106 298
drug self-administration: animal models 80
drug design: and molecular biology 472
drug-efflux pump *see* P-glycoprotein
drug-induced lupus: mechanisms 463
drug metabolism: sex differences 149
drug resistance
anticancer drugs 370
antiviral drugs 333
pyrimethamine 303
Duchenne muscular dystrophy 437
Dunzelt, Walter: and theory of narcosis 265
dystrophin 437

**E**ating disorders: and 5-HT 56
EDRF (endothelium-derived relaxing factor) 427
and $Ca^{2+}$ antagonists 301
*see also* nitric oxide
EGF (epidermal growth factor)
and cancer 126
and receptor-mediated endocytosis 458
signal transduction 360, 411
structure–function studies 211
eicosanoids: and aspirin 455
(s)-emopamil: in cerebral ischemia 215
endocrine pathology: animal models 301
endocytosis, receptor-mediated 458
endonucleases: and cell death 283
β-endorphin: and memory 345
endothelial cells: and ischemia 26
endothelin 47, 374
and PAF 257
and sarafotoxins 212, 375
endotoxic shock: and PAF 257
ephedrine 244
EpDIF (epithelial-derived inhibitory factor) 489
epinephrine 61
epithelium: in airway 489
*erbB* oncogene 126, 411
ergosterol: and cytochrome P-450 358
erythrononyladenine 340
erythroxylum 247
estrogen: and breast cancer 126
etacrynic acid 370
ethosuximide: hypersensitivity 466
9-ethyl-10-methylanthracene: and cytochrome P-450 357
ethynylestradiol: and cytochrome P-450 108
etomoxir 495
etoposide: resistance 370
etyrapone 247
eumelanins 60
excitatory amino acid receptors: and mussel poisoning 15 (Letter)
*see also* NMDA; NMDA receptors
exifone 4

**F**asiculins 259
felodipine 508
fenfluramine 56, 308
FG-1742 473
fish, raw: and parasites 313
flumazenil 473
flunarizine 215, 299, 398
fluoxetine 56
flurbiprofen 453
forskolin 324, 442
FSH (follicle-stimulating hormone): and receptor-mediated endocytosis 459
Fuller, Ray: and the Catecholamine Club 101
fura-2 8, 320

**G** protein-coupled receptor superfamily 64, 208
G proteins
in congestive heart failure 384
and leukotriene receptors 103
and receptor theory 19
subunits 208
$G_i$
and $\alpha_2$-adrenoceptors 14 (Letter)
and dopamine $D_2$ receptors 76
$G_p$
and $G_s$ 210
and phospholipase C 114
GABA 245
$GABA_A$ receptors
modulation by steroids 6
structure/molecular biology 50, 210, 407, 476
$GABA_B$ receptors 401
galanin 432
gastrin: as mitogen 88
*see also* CCK
gastrin receptors 422
non-peptide ligands 272
*see also* CCK receptors
gastritis: and *Campylobacter pylori* 37
gastrointestinal motility disorders: and $Ca^{2+}$ antagonists 170
glibenclamide 431
glomerular nephritis: and PAF 257
Glowinski, Jaques: and the Catecholamine Club 100
glucagon
and glucose–fatty acid cycle 496
and receptor-mediated endocytosis 459
gluconeogenesis 496
glucose–fatty acid cycle 496
glucose transporter: and forskolin 442
γ-glutamylcysteine synthetase: and anticancer drugs 372
glutathione
and cell death 275
as chemoprotector 370
and cysteine 485
glycine receptor: structure 50, 210
glycogenolysis: and PAF 10
Gly-Gln: and acetylcholinesterase 136 (Letter)
Goldberg, Leon I.::Obituary 259
Goldstein, Menek: and the Catecholamine Club 101
goserelin 270
GR-38032F (odansetron) 127, 172
GR-43175: and migraine 89, 200
gramicidin: 3-D structure 71
granisetron (BRL-43694) 127
growth factor receptors: and phospholipase C 360
growth factors: and cancer 125
growth hormone
and cytochrome P-450 149
and receptor-mediated endocytosis 459
guanabenz 343 and 467 (Errata)
G-CSF (granulocyte-colony stimulating factor): and anticancer therapy 154, 169
GM-CSF (granulocyte–macrophage colony-stimulating factor)
and cancer therapy 154
and PAF 28

**H**-7 218, 236
H-87/67 317
hallucinogens: self-administration by animals 80
haloperidol 501
heart '$\beta_3$' receptor 316
heart failure: and signal transduction 383
Heidegger 133
heparin: and acetylcholinesterase 325
Herpesvirus: drug resistance 335
Hill coefficients: and the logistic equation 440
hirudin: discovery 99 (Letter)
histamine: and airway narrowing 489
histamine $H_2$ receptor antagonists: and duodenal ulcers 38
histamine $H_3$ receptors 159
in airways 264 (Letter)
histamine receptors ($H_1$, $H_2$) 245
HIV (human immunodeficiency virus) proteinase: and drug design 305
HIV reverse transcriptase: and antisense oligonucleotides 436
homomeric ion channels 210
hopatenate 4
5-HT
and Alzheimer's disease 3
and eating disorders 56
and phosphoinositide turnover 115
5-HT autoreceptors: species differences 130
5-HT receptors
and β-adrenoceptor ligands 318
in coronary circulation 89
and drug addiction 127
molecular biology 64
and schizophrenia 127
$5\text{-HT}_1$-like receptor agonists: and migraine 2, 89, 200, 307
$5\text{-HT}_1$-like receptors
and anorexia 56
and autoinhibition 130
in coronary circulation 89
$5\text{-HT}_{1A}$ receptor agonists: and eating disorders 56
$5\text{-HT}_{1A}$ receptors
molecular biology 64
and phosphoinositide metabolism 118
and renal blood flow 470
$5\text{-HT}_{1C}$ receptors
and migraine 1, 200, 307

molecular biology 51, 64
5-$HT_2$ receptors
and cerebral ischemia 215
in coronary circulation 90
and eating disorders 56
and migraine 1
molecular biology 51, 64
5-$HT_3$ receptors
and dopamine 127
electrophysiology 172
5-$HT_4$ receptors 385
5-HT reuptake inhibitors 247
Huntington's disease: and NGF 145
hydralazine: hypersensitivity 464
hydroxymethylglutaryl-CoA reductase: inhibitors 472
2-hydroxysaclofen 403
hypersensitivity reactions: mechanisms 463
hypertension
and $Ca^{2+}$ antagonists 300
and CRF 192
and signal transduction 383
hypoglycemic drugs 495

**I**buprofen: stereochemistry 352
ICAM-1 (intercellular adhesion molecule): and rhinovirus 387
ICRF-187 370
ICS 205-930 127, 172, 385
idazoxan 342 and 467 (Errata)
idebenone 4
IGF-I (insulin-like growth factor)
and thyroid hyperplasia 302
and receptor-mediated endocytosis 459
IL-1 (interleukin 1)
and PAF 28
and receptor-mediated endocytosis 459
IL-2 (interleukin 2)
and PAF 28
receptor 239
and receptor-mediated endocytosis 459
IL-3 (interleukin 3): in bone marrow 169
imidazoline binding sites 342 and 467 (Errata)
immune system: and β-adrenoceptors 384
immunity: and prolactin 40
immunotoxicology 289
impromidine 161
indole alkaloids 370
inflammation: and neuropeptides 91
influenza A: drug resistance 333
inositol phosphates: phosphorothioate analogs 142
INPEA 317
insulin
and glucose–fatty acid cycle 495
and receptor-mediated endocytosis 458
interferons: and receptor-mediated endocytosis 459
interferon-γ: and PAF 28
intermittent claudication: and $K^+$ channel openers 431
iodocyanopindolol 319
iodohydroxybenzylpindolol 319
5-iodotubericidin 340
$IP_3$ (inositol 1,4,5-trisphosphate)
and $Ca^{2+}$ release 9
metabolizing enzymes 141
receptors 139
$IP_4$ (inositol 1,3,4,5-tetrakisphosphate)
and $Ca^{2+}$ entry 9
receptors 139
irritable bowel syndrome: and $Ca^{2+}$ antagonists 170
ischemia: and PAF antagonists 23, 256
ischemia, cardiac
and $Ca^{2+}$ antagonists 300
new drugs 397
and PAF antagonists 24
and signal transduction 383
ischemia, cerebral
and $Ca^{2+}$ antagonists 300
and dextromethorphan 505
and (s)-emopamil 215
and $K^+$ channel openers 431
new drugs 400
and PAF antagonists 23
isobutylthioadenosine 340
isobutylthioinosine 340
isoguvacine 407
isoniazid: hypersensitivity 467
isoproterenol 324

**J**et travel, hazards 134

**K**-252: and protein kinases 218
$K^+$ channel openers
as antiarrhythmics 35
sites of action 431
$K^+$ channels, ATP-sensitive 431
$K^+$ channels, voltage-sensitive
and forskolin 443
in heart 35
kadsurenone 24
ketoconazole 273
stereochemistry 352
ketogenesis 497
KL-105 317
Kopin, Irwin: and the Catecholamine Club 100
Krayer, Otto: and the Nazis 134
kynurenic acid: and mussel poisoning 15 (Letter)

**L**-364,718 422
L-365,260 272, 422
labetalol: stereochemistry 350
lateral mobility of cell surface components: measurement 95
lead: and the immune system 291
learning
and stress 475
*see also* memory
Lefkowitz, Bob: and the Catecholamine Club 100
[Leu]enkephalin 72
and memory 345
leucovorin: stereochemistry 352
leukocytes: and ischemia 26
leukotriene biosynthesis: and neuropeptides 91
leukotriene receptors ($B_4$, $D_4$): signal transduction 103
levodopa 54
LH (luteinizing hormone): and receptor-mediated endocytosis 459
LHRH (luteinizing hormone-releasing hormone) 72
non-peptide receptor antagonists 273
therapy 302
lidoflazine 215
ligand binding domains: structure–function studies 208
ligands, non-peptide: for peptide receptors 270
lipoid theory of narcosis: history 265
lipomodulin 413
5-lipoxygenase: and leukotriene biosynthesis 104
LND 623 13
logistic equation: and Hill coefficients 440
long-term potentiation: and protein kinase C 236
lorglumide 272
lovastatin: enzyme target 306
low-dose aspirin 453
loxiglumide 272
LU-49888 298

**M**alaria 303
male pattern baldness: and steroid 5α-reductase inhibitors 491
Manger, William: and the Catecholamine Club 100
*mas* oncogene: and angiotensin receptors 87
MDL-72222 127, 172
melittin: and long-term potentiation 236
melphalan 372
memory
animal models 4
and endorphins 345
*see also* learning
menadione 279
mepacrine 371
meproadifen 448
mephenytoin: and cytochrome P-450 108
message–address concept 230
metallothioneins: and cancer chemotherapy 372
methadone 247
methamphetamine 247
methanediol 391
methotrexate: enzyme target 306
β-5-methoxybenzo[*b*]furan-2-yl-GABA 403
5-methoxytryptamine 385
*N*-methyl-D-aspartate *see* NMDA
*n*-methylatropine 245
methylcholanthrene: and the immune system 291
α-methylhistamine 160
2-methyl-5-HT 172, 385
methylmercury: and the immune system 291
*S*-methyl-3-(methylthio)thiopropionate 391
methyl palmoxirate (2-TDGA) 495
methylphenidate 247
*S*-methylthioacrylate 391
mercapturic acids: and toxicological studies 177
metiamide: adverse reactions 463
metoclopramide 247, 385
Meyer, Hans Horst: and lipoid theory of narcosis 265
migraine
and 5-$HT_1$-like receptor agonists 2, 89, 200, 307
vascular and neurogenic theories 1
minoxidil 431
mioflazine 340
mitogenic hormones: and cancer 126
mitogenic peptides 88
mitomycin 372
MK-212 308
MK-329 272
MK-801 503
MK-906 493
moctamide: stereochemistry 351
molecular biology
cloning receptors 346
and drug design 472
of receptors 50, 64, 207
*see also named receptors*
MOM: and pharmacokinetic studies 480
morphine 271
and adenosine 186 and 316 (Letter)
motion sickness: and space flight 199, 243
α-MSH (α-melanotropin): structure 72
multidrug resistance genes (*mdr*)
and pyrimethamine resistance 303
*see also* P-glycoprotein
muscarinic acetylcholine receptors 52
and membrane composition 96
subtypes 69
and transmitter release 110
muscimol 404, 407
mussel poisoning: and excitatory amino acid receptors 15 (Letter)
*myc* oncogene: in breast cancer 127
myeloperoxidase: and hypersensitivity 464
myocardial infarction 400
myosin light chain kinase: and vasoconstriction 219, 323

**N**a$^+$ channels: lateral mobility 95
$Na^+/K^+$-transporting ATPase 11
nabilone 247

naloxone 185, 230, 271
naltrexone 230
naltrindole 235, 271
naproxen: enantioselective synthesis 472
narcosis: lipoid theory 265
*see also* anesthetic action
Nazis: and phosgene experiments 133
neuropeptides: and inflammatory mediators 91
neuroprotection: by dextromethorphan 501
neurotoxins: 'long' and 'short' 259
NFG (nerve growth factor)
and $Ca^{2+}$ channels 298
and cholinergic neurons 145
and receptor-mediated endocytosis 459
nicardipine 215, 508
nicorandil 432
nicotinic acetylcholine receptors
and anesthetic action 447
and forskolin 443
and $GABA_A$ receptor 410
lateral mobility 95
structure 50, 210
subtypes 210
and transmitter release 110
nicotinic autofacilitation 112
nifedipine 215, 507
and cytochrome P-450 108
nimodipine 508
nisoldipine 508
nitrates: in ischemia 397
nitrazepam 408
nitrendipine 508
nitrosoureas 372
NMDA: and phosphoinositide metabolism 118
NMDA receptors
and dextromethorphan 501
and long-term potentiation 236
and NO release 428
L-NMMA ($N^G$-monomethyl-L-arginine): and NO synthesis 428
NO (nitric oxide) 427
and 5-$HT_1$-like receptors 89
*see also* EDRF
NO synthase 428
nomifensine: hypersensitivity 466
noradrenaline *see* norepinephrine
norbinaltorphimine 232, 271
norepinephrine
and Alzheimer's disease 3
in the circulation 61
5'-nucleotidase: and adenosine metabolism 339
null method: vs operational model 16 (Letter)

**O**dansetron (GR-38032F) 127, 172
oestrogen *see* estrogen
olive oil: cardioprotective properties 314
oncogenes
and growth factors 125
*see also mas, erbB, myc, ras*
operational model: vs null method 16 (Letter)
opiates 501
opioid receptor antagonists: design 230
opioid receptors: non-peptide ligands 270
δ-opioid receptors: and antinociception 183
κ-opioid receptors 52
opioids
and CRF 192
self-administration by animals 80
opsins: and G protein-coupled receptor superfamily 51, 69
OR-462 55
organotin compounds: and the immune system 291
ornithine decarboxylase: and prolactin 41
ouabain 13
Overton, Charles Ernest: and theory of narcosis 266
oxazepam: stereochemistry 352
2-oxiranecarboxylates: and diabetes 495
oxothiazolidine-4-carboxylate 370
oxprenolol 31, 317
oxymorphindole 235
oxytocin 270
structure 72

**P**AF (platelet-activating factor) 255
and cytokines 28
and glycogenolysis 10
and ischemia 23
PAF acetylhydrolase 256
PAF antagonists 255
and ischemia 23
PAF–cytokine networks: and the catastrophe theory 26
PALA (*N*-phosphonacetyl-L-aspartate) 494
palatability: and taste aversion 129
2-PAM 247
paracetamol
and cytochrome P-450 357
overdose 278
Parkinson's disease: and COMT inhibitors 54
PCP (phencyclidine)
and dextromethorphan 501
and local anesthesia 448
PDGF (platelet-derived growth factor)
and phospholipase C 362, 411
and receptor-mediated endocytosis 459
PDGF receptor: structure 126
pemoline 247
penicillamine: hypersensitivity 466
penicillin: hypersensitivity 463
pentazocine 501
peptic ulcers 36
peptide histidine–methionine: and inflammatory mediators 91
peptide hormones: and the message–address concept 233
peptide receptors: and non-peptide ligands 270
pesticides: and the immune system 291
P-glycoprotein
modulators 370
structure 208
*see also* multidrug resistance genes
pH-partition data 182
phaclofen 403, 407
phaeomelanins 60
phalloidin: and cell death 281
pharmacogenetics: of addiction 78
pharmacokinetic studies: computer program 480
phenacetin: and cytochrome P-450 109
phenacetin *O*-deethylase 109
phenmetrazine 247
phenobarbital: and cytochrome P-450 288
phenothiazines 370
phenoxyacetylproglumide 421
phentermine 247
phenylalkylamines
receptors 298
*see also named entries*; $Ca^{2+}$ antagonists
$N^{\alpha}$-(4-phenylbutanoyl) histamine 160
phenylephrine 323
8-phenyltheophylline 340
phenytoin 505
hypersensitivity 466
phorbol esters 324, 370
phosgene experiments 133
phosphoinositide turnover
and dopamine $D_2$ receptors 74
and endothelin 48
hormones and growth factors 360
inhibition 114
phospholipase $A_2$
and cell death 282
and $LTD_4$ signal transduction 104
phospholipase-activating protein (PLAP): and $LTD_4$ 104
phospholipase C
and dopamine $D_2$ receptors 74
and growth factor receptors 360, 412
inhibition 114
and $LTD_4$ receptors 103
phospholipase C isozymes 360, 412
picrotoxin: and $GABA_A$ receptors 407
pigments: skin and hair 60
pinacidil 35, 431
pindolol 31, 317
piracelam 4
pituitary–adrenal axis 189
platelets
and aspirin 454
and ischemia 26
plicamycin: resistance 370
PN 200-110 508
polyamines: and the cell cycle 42
polychlorinated hydrocarbons: and the immune system 290
polymerase chain reaction (PCR) 309 and 345 (Errata)
and cloning receptor subtype genes 346
polymyxin B 236
polypeptides: conformation 70
potassium *see* $K^+$
(+)-3-PPP [(+)-3-(3-hydroxyphenyl)-*N*-(1-propyl)piperidine] 501
practolol 316
hypersensitivity 466
stereochemistry 349
pregnanes: and $Na^+/K^+$-ATPase 11
procainamide: hypersensitivity 464
procaterol 317
profen 394 (Letter)
progesterone
as chemoenhancer 370
and cytochrome P-450 109
and $GABA_A$ receptors 6
and $Na^+/K^+$-ATPase 11
proglumide 272
prolactin
and immunity 40
and receptor-mediated endocytosis 459
promethazine 244
propranolol 33
propylthiouracil 466
prostaglandins
and glycogenolysis 10
and vascular smooth muscle 323
prostatic hyperplasia, benign: and steroid 5α-reductase inhibitors 491
proteins: 3-D structure 70
protein kinases
inhibitors 218 and 396 (Letter)
protein kinase C
and $Ca^{2+}$ channel modulation 298
inhibitors 218 and 396 (Letter)
and long-term potentiation 236
in the nucleus 40
protriptyline 247
psychomotor stimulants: self-administration by animals 80
pulegone: and cytochrome P-450 354
$P_2$ purinoceptors 365
pyrimethamine resistance: and point mutations 303
pyrimidinoceptors: and uridine 365

**Q**uin2 8
quinolone resistance 333
quipazine 172

**R**-56865 398
R-58735 398
R-59022 396 (Letter)
R-75319 257
'radical-clock' substrates: and reaction mechanisms 355
ranolazine 399
*ras* oncogene: and breast cancer 127
razoxane 370
σ-receptor: and dextromethorphan 501

receptor classification
and apparent agonist affinity 63 (Letter)
and receptor gene sequences 66
and receptor theory 18
receptor-mediated endocytosis 458
receptor number: and competitive binding data 227
receptor-operated $Ca^{2+}$ channels: and protein kinase C 219
receptor superfamilies 50
G protein-coupled 64, 208
receptor theory
and $pA_2$ analysis 183
and classification 18
receptors, molecular biology 50, 64, 207
cloning receptor subtypes 346
*see also named receptors*
refereeing 17 (Letter)
renzapride (BRL-24924) 385
reproduction: and PAF 256
reserpine 371
rhinitis: and bradykinin 387
rhinovirus 387
rhodopsin: and G protein-coupled receptor superfamily 69
rifampicin: and cytochrome P-450 108
rimantadine resistance: in influenza A 333
Ro 41-0960 55
RP-49356 432
Russell, Diane H.: Obituary 441

**S**-8308 273
saclofen 403
salazosulfapyridine: hypersensitivity 466
salbutamol 317, 350
sarafotoxins 212, 375
SCH-15725 408
SCH-37370 256
schizophrenia 127
scopolamine 243
scopolamine amnesia: and dementia 175
sedative–hypnotics: self-administration by animals 80
senile dementia of the Alzheimer type (SDAT) *see* Alzheimer's disease
sertraline 56
serum cholinesterase: variants 310 and 345 (Errata)
sex differences: in drug and steroid metabolism 149
shock: and PAF 256
signal transduction
in disease 383
and dopamine $D_2$ receptors 74
at EGF receptors 411
at leukotriene $D_4$ receptors 103
*see also* phosphoinositide metabolism
SIGNS nomenclature 349 and 394, 486, 487 (Letters)
SK&F-10047 501
SK&F-86466 343 and 467 (Errata)
SK&F-104353 104
SM-10061 256
smooth muscle, vascular: and $Ca^{2+}$ 320
SMS-201995 302
Snyder, Solomon: and the Catecholamine Club 100
sodium *see* $Na^+$
sodium nitroprusside 324
solflazine 340
somatomedin *see* IGF-I
somatostatin
and $K^+$ channels 432
and receptor downregulation 302
structure 71
$SP_{4-11}$ analogs 421
space flight
and motion sickness 199, 243
pharmacokinetics 193
Spector, Sidney: and the Catecholamine Club 100
spiradoline 503
spreadsheets: and data handling 57
SR-2508 370
SRI 63-441 24
staurosporine: and protein kinases 218
stereochemistry: generic name system (SIGNS) 349 and 394, 486, 487 (Letters)
steroids
as chemoprotectors 370
and forskolin 445
and $GABA_A$ receptors 6
metabolism 149
receptors 211
steroid 5α-reductase inhibitors: and androgen-related disorders 491
streptomycin resistance 333
streptozocin 370
streptozocin-induced diabetes 302
stress
and CRF 189
and learning 475
stroke *see* ischemia, cerebral
subarachnoid hemorrhage: and α-adrenoceptors 329
substance K: as mitogen 88
substance K receptor: molecular biology 51, 69
substance P
and antinociception 186
and inflammatory mediators 91
as mitogen 88
sulfadiazine
enzyme target 306
hypersensitivity 465
sulfonylureas: and diabetes 495
sulindac: stereochemistry 352
sushi 314

**T**achycardias: and adenosine 341
tamoxifen 370
taste aversion 129
TCDD (dioxin)
and apoptosis 280, 284
and cytochrome P-450 genes 285
and the immune system 291
teaching of clinical pharmacology 224
teniposide: resistance 370
tertatolol 470
testosterone
and androgen-related disorders 491
and cytochrome P-450 358
tetanic fade: and nicotinic autofacilitation 112
tetrahydrocannabinol 247
TGFs (transforming growth factors)
and breast cancer (α, β) 126
and receptor-mediated endocytosis (β) 459
theobromine 390
theophylline 340
thiamazol 466
thioperamide 160
thiosulfate 370
thrombosis: and aspirin 453
thromboxane $A_2$ 453
thymopentin: structure 71
thyroid hormones: and receptor-mediated endocytosis 459
tifluadom 271
timolol: stereochemistry 350
TNF (tumor necrosis factor)
and anticancer therapy 169
and PAF 28
and receptor-mediated endocytosis 459
tolazoline 342 and 467 (Errata)
tolbutamide 432
and cytochrome P-450 108
topoisomerase I: and leukotrienes 103
toxicity studies: and mercapturic acids 177
toxins, bacterial 415
toxins, snake
'long' and 'short' neurotoxins 258
sarafotoxins 212, 375
train-of-four fade: and nicotinic autofacilitation 112
tranexamic acid: stereochemistry 351
transmembrane signaling *see* signal transduction
TRH (thyrotropin-releasing hormone): and $PIP_2$ hydrolysis 75, 116
trichochromes 60
trimethadione: hypersensitivity 466
trimethoprim: emzyme target 306
triparanol 370
TSH (thyrotropin) 302
tubocurarine 112
Tyrian purple (6,6'-dibromoindigotin) 61
tyrosine 60
tyrosine kinase: of growth factor receptors 360, 411

**U**-46619 11
U-50488H 52, 271
U-73975 168
UCN-01: and protein kinases 218
UK-14304 343 and 467 (Errata)
uridine: and pyrimidinoceptors 365
urodilatin 93
UTP: and regulation of cell function 365

**V**alerian 315
valproic acid: and cytochrome P-450 359
vasopressin: as mitogen 88
vasospasm, cerebral: and α-adrenoceptors 329
verapamil 215, 324, 507
and multidrug resistance 371
vinblastine: resistance 370
vincristine: resistance 370
VIP (vasoactive intestinal peptide)
and adenylyl cyclase 116
and inflammatory mediators 91

**W**arfarin: stereochemistry 350
WEB-2086 23, 256
WEB-2347 256
weightlessness 195
Weiner, Norman: and the Catecholamine Club 100
WIN 44, 441-3 53

**X**amoterol 317

**Y**M-461 256
yohimbine 246

**Z**acopride 127, 385
zidovudine (AZT)
enzyme target 306
resistance 333
zinoconazole: stereochemistry 351
zolpidem 408